Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tobam

Tobam trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 57.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,268 shares of the company’s stock after selling 41,978 shares during the period. Neurocrine Biosciences makes up about 1.3% of Tobam’s holdings, making the stock its 26th biggest holding. Tobam’s holdings in Neurocrine Biosciences were worth $4,268,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in NBIX. Plato Investment Management Ltd lifted its stake in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after purchasing an additional 10,548 shares in the last quarter. Swiss National Bank lifted its position in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after buying an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp purchased a new stake in Neurocrine Biosciences during the third quarter worth approximately $3,236,000. KBC Group NV increased its position in shares of Neurocrine Biosciences by 78.3% in the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after acquiring an additional 8,332 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Neurocrine Biosciences by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock valued at $2,238,000 after acquiring an additional 7,597 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $150.51 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The company’s fifty day moving average is $138.41 and its two-hundred day moving average is $131.64. The stock has a market capitalization of $15.24 billion, a price-to-earnings ratio of 40.35 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on NBIX. Raymond James reissued an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Piper Sandler reissued an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Barclays upped their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $166.85.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 222,693 shares of company stock valued at $32,718,279. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.